Article Text

Download PDFPDF
They SHALL grow old: a UK rare disease clinical network for adult congenital thoracic malformations
  1. Andy Bush1,2,
  2. Rishi Pabary1,2,
  3. James Allinson2,3,
  4. Matt Hind1,2
  1. 1 Paediatric Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, Middlesex, UK
  2. 2 National Heart and Lung Institute, Imperial College, London, UK
  3. 3 Paediatric Respiratory Medicine, National Heart and Lung Institute Division of Respiratory Science, London, UK
  1. Correspondence to Professor Andy Bush, Paediatric Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London SW3 6NP, Middx, UK; a.bush{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Alexander Pope’s line ‘A little learning is a dangerous thing’ (note: NOT knowledge) is probably one of the most misquoted in all literature, but certainly applies today to many rare diseases. An exemplar is congenital thoracic malformation (CTM, sometimes called congenital lung malformation, congenital pulmonary airway malformation, congenital cystic adenomatoid malformation and a host of other exotic names reflecting a lack of general consensus in management). We first learnt more than 30 years ago that large CTMs can be detected during the mid-pregnancy fetal anomalies scan. Without knowledge of the natural history of these lesions, there was an initial vogue for invasive fetal interventions until it became clear that the majority regressed to the extent that most babies were born well and required no immediate intervention.1 We also learnt that while most lesions remained asymptomatic for many years, serious complications may occur at any age in a small number. These fall into two categories: serious but treatable, such as infection, bleeding and pneumothorax; and the very rare but potentially lethal, namely malignant transformation and air embolism. The lack of knowledge of any biomarkers of adverse outcome, including imaging, has had the predictable result of different centres having different management strategies, variably operating on none, all or some. The field is an evidence-based desert in paediatrics and our relatively limited scientific insights into the biology of CTMs have made management harder, not easier. The recent welcome establishment of a neonatal registry ( offers …

View Full Text


  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.